Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Complete Title: A Phase 1, Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb�819 in Subjects with Relapsed or Refractory Clear Cell Renal Cell Carcinoma
Trial Phase: I
Investigator: Scott Tykodi
The purpose of this study is to assess the safety and tolerability of XmAb®819 administered intravenous (IV) or subcutaneous (SC) in subjects with relapsed or refractory clear cell renal cell carcinoma and to identify the minimum safe and biologically active dose and the recommended dose (RD).
Keywords:
- Carcinoma, Renal Cell
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.